Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 11/2019

01-11-2019 | Overactive Bladder | Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Management Strategies for Nocturia

Authors: Danielle J. Gordon, Curran J. Emeruwa, Jeffrey P. Weiss

Published in: Current Urology Reports | Issue 11/2019

Login to get access

Abstract

Purpose of Review

Nocturia is defined as awakening due to the desire to void during a period of intended sleep. The pathophysiology of nocturia is multifactorial and management remains a challenge. Herein, we provide an overview of the management strategies for nocturia and summarize the existing evidence for treatment of nocturia across the condition’s broad etiologic categories: nocturnal polyuria, diminished bladder capacity, and global polyuria.

Recent Findings

Treatment should begin with behavioral modification. A high level of evidence supports the efficacy of desmopressin in the treatment of nocturnal polyuria. Data supporting the efficacy of α-blockers, antimuscarinics, and surgical bladder outlet procedures in the treatment of nocturia remains limited.

Summary

Treatment options for nocturia are determined by underlying mechanism. Desmopressin is effective in treating nocturnal polyuria. Surgical intervention, α-blockers, and antimuscarinics may improve nocturia when associated with lower urinary tract symptoms or overactive bladder in the setting of diminished bladder capacity.
Literature
1.
Bosch JR, Weiss JP. The prevalence and causes of nocturia. J Urol. 2010;184:440–6.PubMed
2.
Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, Rosen RC. Association of nocturia and mortality: results from the third National Health and Nutrition examination survey. J Urol. 2011;185:571–7.PubMed
3.
Weiss JP, Marshall SD: Nocturia. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh Urology, Eleventh Edition. Elsevier (2016).
4.
Hall MH, Muldoon MF, Jennings JR, Buysse DJ, Flory JD, Manuck SB. Self-reported sleep duration is associated with the metabolic syndrome in midlife adults. Sleep. 2008;31:635–43.PubMedPubMedCentral
5.
Ancoli-Israel S, Bliwise D, Noorgaard JP. Nocturia and sleep disorders. In: Weiss JP, Blaivas JG, Van Kerrebroeck PEV, et al., editors. Nocturia: causes, consequences, and clinical approaches. New York: Springer-Verlag; 2012. p. 37.
6.
Endeshaw YW, Johnson TM, Kutner MH, Ouslander JG, Bliwise DL. Sleep-disordered breathing and nocturia in older adults. J Am Geriatr Soc. 2004;52:957–60.PubMed
7.
8.
Asplund R. The nocturnal polyuria syndrome (NPS). Gen Pharmacol Vasc Syst. 1995;26:1203–9.PubMed
9.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.PubMed
10.
11.
Rottmann CN. SSRIs and the syndrome of inappropriate antidiuretic hormone secretion. Am J Nurs. 2007;107:51–8 quiz 58–9.PubMed
12.
Asplund R, Johansson S, Henriksson S, Isacsson G. Nocturia, depression and antidepressant medication. BJU Int. 2005;95:820–3.PubMed
13.
Otsuka K, Tanaka H, Horinouchi T, Koike K, Shigenobu K, Tanaka Y. Functional contribution of voltage-dependent and Ca2-activated K (BKCa) channels to the relaxation of Guinea-pig aorta in response to natriuretic peptides. J Smooth Muscle Res. 2002;38:117–29.PubMed
14.
15.
Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Investig. 1995;95:1838–45.PubMedPubMedCentral
16.
Reynard C, Yang A. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol. 1998;81:215–8.PubMed
17.
Guilleminault C, Lin C, Gonçalves M, Ramos E. A prospective study of nocturia and the quality of life of elderly patients with obstructive sleep apnea or sleep onset insomnia. J Psychosom Res. 2004;56:511–5.PubMed
18.
•• Victor RG, Li N, Blyler CA, et al. Nocturia as an unrecognized symptom of uncontrolled hypertension in Black men aged 35 to 49 years. J Am Heart Assoc. 2019. https://​doi.​org/​10.​1161/​jaha.​118.​010794 This study links uncontrolled hypertension as an independent determinant of clinically important nocturia in a large cross-sectional community-based study of non-hispanic black men aged 35–49 years. Among 1673 black men, those with hypertension were 56% more likely than men with normotension to have nocturia after adjustment for diabetes mellitus and sleep apnea (adjusted odds ratio, 1.56; 95% CI, 1.25–1.94 [P < 0.0001]).
19.
Feldstein CA. Nocturia in arterial hypertension: a prevalent, underreported, and sometimes underestimated association. J AM Soc Hypertens. 2013;7:75–84.PubMed
20.
Mattiasson A, Abrams P, Kerrebroeck PV, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 2002;89:855–62.PubMed
21.
Lose G, Lalos O, Freeman RM, Kerrebroeck PV. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol. 2003;189:1106–13.PubMed
22.
Weiss JP, Zinner NR, Klein BM, Nørgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31:441–7.PubMed
23.
Sand PK, Dmochowski RR, Reddy J, Meulen EAVD. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190:958–64.PubMed
24.
Weiss JP, Jumadilova Z, Johnson TM, Fitzgerald MP, Carlsson M, Martire DL, et al. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol. 2013;189:1396–401.PubMed
25.
•• Zong H, Yang C, Peng X, Zhang Y. Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials. Int Urol Nephrol. 2011;44:377–84 A meta-analysis of five studies involving 619 participants revealed that desmopressin significantly decreases the frequency of nocturnal voids, nocturnal urine volume, and nocturnal diuresis, resulting in extended duration of the first sleep period and improved sleep quality. The adverse effects of desmopressin were similar to those in the placebo group.PubMed
26.
27.
Yamaguchi O, Nishizawa O, Juul KV, Nørgaard JP. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int. 2012;111:474–84.PubMed
28.
Tomasi P, Siracusano S, Monni A, Mela G, Delitala G. Decreased nocturnal urinary antidiuretic hormone excretion in enuresis is increased by imipramine. BJU Int. 2002;88:932–7.
29.
Giardina EG, Bigger JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60:1045–52.PubMed
30.
Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci. 1997;42:14124J. https://​doi.​org/​10.​1520/​jfs14124j.CrossRef
31.
Brubaker L, Fitzgerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J. 2006;18:737–41.
32.
Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl. 2005;4:61–8.
33.
Epstein MR, Monaghan T, Weiss JP. Etiology of nocturia response in men with diminished bladder capacity. Neurourol Urodyn. 2018;38:215–22.PubMed
34.
Cumming JA, Chisholm GD. Changes in detrusor innervation with relief of outflow tract obstruction. Br J Urol. 1992;69:7–11.PubMed
35.
Margel D, Lifshitz D, Brown N, Lask D, Livne PM, Tal R. Predictors of nocturia quality of life before and shortly after prostatectomy. Urology. 2007;70:493–7.PubMed
36.
Housami F, Abrams P. Persistent detrusor overactivity after transurethral resection of the prostate. Curr Prostate Rep. 2007;5:126–32.
37.
Yoshimura K, Ohara H, Ichioka K, Terada N, Matsui Y, Terai A, et al. Nocturia and benign prostatic hyperplasia. Urology. 2003;61:786–90.PubMed
38.
Van Dijk MM, Wijkstra H, Debruyne FM, De La Rosette JJ, Michel MC. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int. 2010;105:1141–6.PubMed
39.
Simaioforidis V, Papatsoris AG, Chrisofos M, Chrisafis M, Koritsiadis S, Deliveliotis C. Tamsulosin versus transurethral resection of the prostate: effect on nocturia as a result of benign prostatic hyperplasia. Int J Urol. 2011;18:243–8.PubMed
40.
Johnson TM, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative study trial. J Urol. 2003;170:145–8.PubMed
41.
Cornu J-N, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and meta-analysis. Eur Urol. 2012;62:877–90.PubMed
42.
Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67:731–6.PubMed
43.
Weiss JP, Herschorn S, Albei CD, Meulen EAVD. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190:965–72.PubMed
44.
Johnson TM, Burrows PK, Kusek JW, Nyberg LM, Tenover JL, Lepor H, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178:2045–51.PubMed
45.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. Jama. 2006;296:2319–28.PubMed
46.
47.
48.
Weiss JP, Blaivas JG, Stember DS, Brooks MM. Nocturia in adults: etiology and classification. Neurourol Urodyn. 1998;17:467–72.PubMed
49.
Vaughan CP, Endeshaw Y, Nagamia Z, Ouslander JG, Johnson TM. A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results. BJU Int. 2009;104:69–74.PubMed
50.
Johnson TM, Markland AD, Goode PS, Vaughan CP, Colli JL, Ouslander JG, et al. Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia. BJU Int. 2013;112:100–8.PubMed
51.
Tani M, Hirayama A, Torimoto K, Matsushita C, Yamada A, Fujimoto K. Guidance on water intake effectively improves urinary frequency in patients with nocturia. Int J Urol. 2014;21:595–600.PubMed
Metadata
Title
Management Strategies for Nocturia
Authors
Danielle J. Gordon
Curran J. Emeruwa
Jeffrey P. Weiss
Publication date
01-11-2019
Publisher
Springer US
Published in
Current Urology Reports / Issue 11/2019
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-019-0940-2

Other articles of this Issue 11/2019

Current Urology Reports 11/2019 Go to the issue

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Neobladder-Vaginal Fistula: Surgical Management Techniques

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Female Urethral Strictures: Review of Diagnosis, Etiology, and Management

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Prolapse Repair Using Non-synthetic Material: What is the Current Standard?

Pediatric Urology (D Weiss, Section Editor)

Early Vs. Expectant Management of Spina Bifida Patients—Are We All Talking About a Risk Stratified Approach?

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Education (G Badalato, Section Editor)

Urology in Undergraduate Medical Education